WRBC
ESLA icon

W.R. Berkley Corp’s Estrella Immunopharma ESLA Stock Holding History

W.R. Berkley Corp’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-54,401
Closed -$547K – 344
2022
Q3 		$547K Hold
54,401
– – 0.03% 427
2022
Q2 		$544K Hold
54,401
– – 0.03% 439
2022
Q1 		$543K Hold
54,401
– – 0.03% 443
2021
Q4 		$539K Hold
54,401
– – 0.03% 433
2021
Q3 		$539K Buy
+54,401
New +$535K 0.04% 328

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

W.R. Berkley Corp's ESLA Position: Q4 2022 in Review

W.R. Berkley Corp sold out of Estrella Immunopharma (ESLA) in Q4 2022, closing a stake of 54,401 shares — an estimated $547K sold.

W.R. Berkley Corp first reported a position in ESLA in Q3 2021 and held it in 5 quarters. The position peaked at $547K in Q3 2022. 13 funds tracked by Wall St. Rank hold ESLA as of Q4 2022.

  • W.R. Berkley Corp reported no remaining Estrella Immunopharma position as of Q4 2022 after selling out during the quarter.
  • W.R. Berkley Corp sold 54,401 Estrella Immunopharma shares in Q4 2022, an estimated $547K.
  • W.R. Berkley Corp first reported a position in Estrella Immunopharma in Q3 2021 and held it in 5 quarters.
  • W.R. Berkley Corp's Estrella Immunopharma position peaked at $547K in Q3 2022.
  • 13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2022.

Based on W.R. Berkley Corp's 13F filing for Q4 2022, filed 14 Feb 2023.